Browse drugs

…ed so far. In Part A, 9 patients in three dose cohorts received ILKN421H. All patients demonstrated high and prolonged plasma level of I…

… B, Feinstein T, Shi Y, et al. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progr…

…treatment samples and in responders.Conclusions Lenvatinib plus pembrolizumab demonstrated encouraging efficacy when used as neoadjuvant ther…

… of definitive surgery who had received chemotherapy along with Pembrolizumab as neoadjuvant settings. After the definitive surgery the biops…

…LITT+PEM) or non-LITT surgery (biopsy or resection) followed by pembrolizumab (NLS+PEM). After 21 patients, randomization was halted when eme…

…mary objective of dose escalation is to determine MTD and RP2D. Pembrolizumab (200 mg IV) will be given with micvo at escalating doses starti…

…ing.Conclusions Preliminary dose escalation data are promising. BI-1910 monotherapy shows a favorable safety and tolerability profile, …

… blood samples collected from patients treated with monotherapy CX-801.Results PK analysis demonstrated dose-proportional exposure of …

…7), as of 28Feb2025, 29 patients with CPI-R/R melanoma received pembrolizumab (400 mg IV Q6W) plus mRNA-4359 (400 µg [n=14] or 1000 µg [n=15]…

…, et al. KEYNOTE-689: phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectabl…

…r exceeding (>50X higher) pharmacodynamic responses reported to vidutolimod, yet with minimal inflammatory cytokine secretion. RNA-seq show…

…d/pleomorphic liposarcoma, addition of neoadjuvant and adjuvant pembrolizumab to preoperative radiation therapy (RT) and surgery improved 2-y…